Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Perceived messages about bone health after a fracture are not consistent across healthcare providers.

Sale JE, Hawker G, Cameron C, Bogoch E, Jain R, Beaton D, Jaglal S, Funnell L.

Rheumatol Int. 2015 Jan;35(1):97-103. doi: 10.1007/s00296-014-3079-y. Epub 2014 Jun 25. Erratum in: Rheumatol Int. 2015 Jan;35(1):105.

PMID:
24962740
2.

Decision to take osteoporosis medication in patients who have had a fracture and are 'high' risk for future fracture: a qualitative study.

Sale JE, Gignac MA, Hawker G, Frankel L, Beaton D, Bogoch E, Elliot-Gibson V.

BMC Musculoskelet Disord. 2011 May 9;12:92. doi: 10.1186/1471-2474-12-92.

3.

Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy's fracture clinic screening program.

Beaton DE, Dyer S, Jiang D, Sujic R, Slater M, Sale JE, Bogoch ER; Osteoporosis Fracture Clinic Screening Program Evaluation Team.

Osteoporos Int. 2014 Jan;25(1):289-96. doi: 10.1007/s00198-013-2430-6. Epub 2013 Jun 21.

PMID:
23794044
4.

Strategies used by an osteoporosis patient group to navigate for bone health care after a fracture.

Sale JE, Cameron C, Hawker G, Jaglal S, Funnell L, Jain R, Bogoch E.

Arch Orthop Trauma Surg. 2014 Feb;134(2):229-35. doi: 10.1007/s00402-013-1889-0. Epub 2013 Nov 26.

PMID:
24276358
5.

Patient perceptions of provider barriers to post-fracture secondary prevention.

Sale JE, Bogoch E, Hawker G, Gignac M, Beaton D, Jaglal S, Frankel L.

Osteoporos Int. 2014 Nov;25(11):2581-9. doi: 10.1007/s00198-014-2804-4. Epub 2014 Aug 1.

PMID:
25082555
6.

Non-pharmacological strategies used by patients at high risk for future fracture to manage fracture risk--a qualitative study.

Sale JE, Gignac MA, Hawker G, Beaton D, Bogoch E, Webster F, Frankel L, Elliot-Gibson V.

Osteoporos Int. 2014 Jan;25(1):281-8. doi: 10.1007/s00198-013-2405-7. Epub 2013 Jun 6.

PMID:
23740423
7.

Patients reject the concept of fragility fracture--a new understanding based on fracture patients' communication.

Sale JE, Gignac MA, Frankel L, Hawker G, Beaton D, Elliot-Gibson V, Bogoch E.

Osteoporos Int. 2012 Dec;23(12):2829-34. doi: 10.1007/s00198-012-1914-0. Epub 2012 Feb 7.

PMID:
22310958
8.

It is time for everyone to own the bone.

Bunta AD.

Osteoporos Int. 2011 Aug;22 Suppl 3:477-82. doi: 10.1007/s00198-011-1704-0. Epub 2011 Aug 17.

PMID:
21847769
9.

Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.

Zarowitz BJ, Cheng LI, Allen C, O'Shea T, Stolshek B.

J Am Med Dir Assoc. 2015 Apr;16(4):341-8. doi: 10.1016/j.jamda.2015.01.073. Epub 2015 Feb 25.

PMID:
25726417
11.

Osteoporosis and vertebral compression fractures-continued missed opportunities.

Freedman BA, Potter BK, Nesti LJ, Giuliani JR, Hampton C, Kuklo TR.

Spine J. 2008 Sep-Oct;8(5):756-62. doi: 10.1016/j.spinee.2008.01.013. Epub 2008 Mar 17.

PMID:
18343730
12.

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R.

J Bone Miner Res. 2012 Feb;27(2):243-54. doi: 10.1002/jbmr.1494. Erratum in: J Bone Miner Res. 2012 Dec;27(12):2612.

13.

Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 1.

14.

Partnership for fragility bone fracture care provision and prevention program (P4Bones): study protocol for a secondary fracture prevention pragmatic controlled trial.

Gaboury I, Corriveau H, Boire G, Cabana F, Beaulieu MC, Dagenais P, Gosselin S, Bogoch E, Rochette M, Filiatrault J, Laforest S, Jean S, Fansi A, Theriault D, Burnand B.

Implement Sci. 2013 Jan 24;8:10. doi: 10.1186/1748-5908-8-10.

15.

Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.

Ganda K, Schaffer A, Pearson S, Seibel MJ.

Osteoporos Int. 2014 Apr;25(4):1345-55. doi: 10.1007/s00198-013-2610-4. Epub 2014 Jan 21.

PMID:
24445732
16.

Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis.

Silverman S, Calderon A, Kaw K, Childers TB, Stafford BA, Brynildsen W, Focil A, Koenig M, Gold DT.

Osteoporos Int. 2013 Jul;24(7):2067-77. doi: 10.1007/s00198-012-2241-1. Epub 2012 Dec 18.

PMID:
23247328
17.

Screening and treatment of osteoporosis after hip fracture: comparison of sex and race.

Antonelli M, Einstadter D, Magrey M.

J Clin Densitom. 2014 Oct-Dec;17(4):479-83. doi: 10.1016/j.jocd.2014.01.009. Epub 2014 Mar 20.

PMID:
24657109
18.

Optimizing fracture prevention: the fracture liaison service, an observational study.

Eekman DA, van Helden SH, Huisman AM, Verhaar HJ, Bultink IE, Geusens PP, Lips P, Lems WF.

Osteoporos Int. 2014 Feb;25(2):701-9. doi: 10.1007/s00198-013-2481-8. Epub 2013 Sep 13.

PMID:
24030287
19.

Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005 and 2008.

McGowan B, Bennett K, Casey MC, Doherty J, Silke C, Whelan B.

Ir J Med Sci. 2013 Dec;182(4):601-8. doi: 10.1007/s11845-013-0935-9. Epub 2013 Mar 13.

PMID:
23483361
20.

Bone health management in men undergoing ADT: examining enablers and barriers to care.

Damji AN, Bies K, Alibhai SM, Jones JM.

Osteoporos Int. 2015 Mar;26(3):951-9. doi: 10.1007/s00198-014-2997-6. Epub 2014 Dec 20.

PMID:
25526712
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk